
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion is a commercial-stage healthcare technology company with a strong IP moat, highlighted by the recent issuance of a new US patent for pain assessment using MRS data. This supports the company's first-mover advantage in the chronic low back pain market, where it has a sizeable available market opportunity of over $400 million in the US alone. With a solid balance sheet of over $21 million in cash and a growing number of commercial agreements and clinical trials in progress, Aclarion's commercial momentum is expected to continue. Although the company's share count has increased, we maintain a positive outlook and have adjusted our 12-month price target to $7.50 to reflect these developments.
Bears say
Aclarion is a healthcare technology company with high operating expenses due to increased investments in sales, R&D, and IR. Potential risks to reaching share price targets include liquidity concerns, regulatory hurdles, and competition, as well as changes in consumer attitudes and macroeconomic factors. It receives a "neutral" rating from Ascendiant Capital Markets, LLC based on these factors.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares